Crystal Denlinger
#173,928
Most Influential Person Now
American medical oncologist
Crystal Denlinger's AcademicInfluence.com Rankings
Crystal Denlingermedical Degrees
Medical
#3627
World Rank
#4111
Historical Rank
Oncology
#266
World Rank
#274
Historical Rank
Download Badge
Medical
Why Is Crystal Denlinger Influential?
(Suggest an Edit or Addition)According to Wikipedia, Crystal Denlinger is an American medical oncologist. In 2021, she was appointed the Chief Scientific Officer of the National Comprehensive Cancer Network. Early life and education Denlinger was born to parents Edgar and Cynthia in New Jersey and grew up alongside her brother Craig. She obtained her medical degree from New Jersey Medical School and completed her internal medicine residency at Mount Sinai Medical Center. Following this, she completed her fellowship in hematology/oncology at Temple University's Fox Chase Cancer Center. Denlinger later said that she chose to pursue a career in oncology after her father was diagnosed with kidney cancer.
Crystal Denlinger's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. (2019) (576)
- Gastric Cancer, Version 3.2016; Clinical Practice Guidelines in Oncology (2016) (544)
- KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. (2020) (430)
- Esophageal and esophagogastric junction cancers, version 1.2015. (2015) (396)
- Gastric Cancer, Version 2.2013 (2013) (364)
- Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. (2016) (343)
- American College of Sports Medicine Roundtable Report on Physical Activity, Sedentary Behavior, and Cancer Prevention and Control (2019) (320)
- Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. (2013) (306)
- Esophageal and esophagogastric junction cancers. (2011) (276)
- The challenges of colorectal cancer survivorship. (2009) (251)
- Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma (2016) (190)
- Defining Venous Involvement in Borderline Resectable Pancreatic Cancer (2010) (126)
- Survivorship: introduction and definition. Clinical practice guidelines in oncology. (2014) (109)
- Weight management and physical activity throughout the cancer care continuum (2017) (99)
- Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. (2018) (98)
- Colorectal Cancer Survivorship: Movement Matters (2011) (84)
- Pancreas Cancer‐Associated Weight Loss (2018) (82)
- Survivorship in Non-Small Cell Lung Cancer: Challenges Faced and Steps Forward. (2015) (82)
- New NCCN guidelines for survivorship care. (2013) (82)
- NCCN guidelines® insights survivorship, version 1.2016 featured updates to the NCCN Guidelines (2016) (80)
- Survivorship, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. (2017) (75)
- Significance of Pathologic Response to Preoperative Therapy in Pancreatic Cancer (2010) (75)
- Lifestyle Factors in Cancer Survivorship: Where We Are and Where We Are Headed (2015) (74)
- Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures: Summary of an FDA and Critical Path Institute Workshop. (2017) (66)
- Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials (2020) (61)
- Perspectives of HER2-targeting in gastric and esophageal cancer (2017) (58)
- Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma (2019) (56)
- Senior adult oncology. (2012) (55)
- Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal Adenocarcinomas. (2016) (54)
- Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial (2021) (53)
- NCCN Guidelines Insights: Survivorship, Version 1.2016. (2020) (53)
- NCCN Guidelines Insights: Survivorship, Version 2.2020. (2020) (52)
- Effect of Home-Based Exercise and Weight Loss Programs on Breast Cancer-Related Lymphedema Outcomes Among Overweight Breast Cancer Survivors: The WISER Survivor Randomized Clinical Trial. (2019) (50)
- Epirubicin and Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy for Early Breast Cancer (2007) (49)
- Prognostic Significance of MUC-1 in Circulating Tumor Cells in Patients With Metastatic Pancreatic Adenocarcinoma (2016) (49)
- Survivorship: healthy lifestyles, version 2.2014. (2014) (46)
- Challenges in the management of older patients with colon cancer. (2012) (45)
- Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors (2015) (44)
- Impact of the radiation boost on outcomes after breast-conserving surgery and radiation. (2011) (44)
- NCCN Clinical Practice Guidelines Occult primary. (2011) (40)
- Survivorship: Cognitive function, Version 1.2014; Clinical practice guidelines in oncology (2014) (38)
- Phase I study of AMG 510, a novel molecule targeting KRAS G12C mutant solid tumours (2019) (36)
- NCCN Guidelines Insights: Survivorship, Version 2.2019. (2019) (34)
- Survivorship, version 2.2019 featured updates to the NCCN guidelines (2019) (33)
- Neoadjuvant Chemoradiation and Duration of Chemotherapy Before Surgical Resection for Pancreatic Cancer: Does Time Interval Between Radiotherapy and Surgery Matter? (2014) (33)
- Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors (2009) (33)
- Esophageal and Esophagogastric Junction Cancers Clinical Practice Guidelines in Oncology (2011) (32)
- Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer (2014) (31)
- Survivorship: nutrition and weight management, Version 2.2014. Clinical practice guidelines in oncology. (2014) (31)
- The women in steady exercise research (WISER) survivor trial: The innovative transdisciplinary design of a randomized controlled trial of exercise and weight-loss interventions among breast cancer survivors with lymphedema. (2017) (31)
- OA02.02 Phase 1 Study of Safety, Tolerability, PK and Efficacy of AMG 510, a Novel KRASG12C Inhibitor, Evaluated in NSCLC (2019) (29)
- A phase 1 study of MM-111, a bispecific HER2/HER3 antibody fusion protein, combined with multiple treatment regimens in patients with advanced HER2-positive solid tumors. (2014) (29)
- Survivorship: cognitive function, version 1.2014. (2014) (28)
- Ramucirumab (RAM) or merestinib (MER) or placebo (PL) plus gemcitabine (GEM) and cisplatin (CIS) as first-line treatment for advanced or metastatic biliary tract cancer (BTC): A randomized, double-blind, phase II study. (2020) (27)
- Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial. (2007) (27)
- Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma. (2016) (27)
- Development and preliminary testing of PROGRESS: a Web-based education program for prostate cancer survivors transitioning from active treatment (2015) (26)
- Survivorship: fatigue, version 1.2014. (2014) (26)
- Safety, tolerability, and pharmacokinetics of TAK-701, a humanized anti-hepatocyte growth factor (HGF) monoclonal antibody, in patients with advanced nonhematologic malignancies: First-in-human phase I dose-escalation study. (2010) (26)
- A Phase II Study of Capecitabine, Oxaliplatin, and Cetuximab with or Without Bevacizumab as Frontline Therapy for Metastatic Colorectal Cancer. A Fox Chase Extramural Research Study (2012) (24)
- Progress in the Development of Prognostic and Predictive Markers for Gastrointestinal Malignancies (2007) (24)
- A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancers. (2014) (24)
- Fluoropyrimidine Cardiotoxicity: Time for a Contemporaneous Appraisal (2019) (24)
- First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer. (2019) (24)
- Survivorship: sleep disorders, version 1.2014. (2014) (23)
- Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors (2020) (23)
- Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer (2020) (22)
- Survivorship, Version 1.2021. (2021) (21)
- Gastric cancer. (2010) (21)
- Survivorship: Fatigue, Version 1.2014: Clinical Practice Guidelines in Oncology (2014) (21)
- Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance) (2019) (20)
- A phase I/II and pharmacologic study of MM-111 in patients with advanced, refractory HER2-positive (HER2+) cancers. (2010) (19)
- CodeBreak 100: Activity of AMG 510, a novel small molecule inhibitor of KRASG12C, in patients with advanced colorectal cancer. (2020) (19)
- Phase 1b study of WNT inhibitor vantictumab (VAN, human monoclonal antibody) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (PC) (2016) (18)
- Pembrolizumab (P) monotherapy in patients with previously treated metastatic high grade neuroendocrine neoplasms (HG-NENs). (2018) (17)
- Survivorship: sexual dysfunction (female), version 1.2013. (2014) (16)
- Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study. (2021) (15)
- FRACTION (Fast Real-time Assessment of Combination Therapies in Immuno-Oncology)-gastric cancer (GC): A randomized, open-label, adaptive, phase 2 study of nivolumab in combination with other immuno-oncology (IO) agents in patients with advanced GC. (2017) (15)
- Survivorship: immunizations and prevention of infections, version 2.2014. (2014) (15)
- Oxaliplatin: Detection and Management of Hypersensitivity Reactions. (2019) (14)
- Survivorship: screening for cancer and treatment effects, version 2.2014. (2014) (13)
- Randomized phase 2 study of paclitaxel (PTX), trastuzumab (T) with or without MM-111 in HER2 expressing gastroesophageal cancers (GEC). (2016) (13)
- Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial (2007) (12)
- Phase Ib study of WNT inhibitor ipafricept (IPA) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (mPC). (2019) (12)
- Safety and efficacy of durvalumab in combination with tremelimumab, durvalumab monotherapy, and tremelimumab monotherapy in patients with advanced gastric cancer. (2018) (11)
- A phase II trial of the proteasome inhibitor bortezomib in patients with recurrent or metastatic adenocarcinoma of the bile duct or gallbladder (NCI #6135). (2009) (11)
- Lack of pharmacokinetic drug–drug interaction between ramucirumab and paclitaxel in a phase II study of patients with advanced malignant solid tumors (2016) (11)
- Diffuse gastric cancer: histologic, molecular, and genetic basis of disease. (2020) (11)
- Survivorship: pain version 1.2014. (2014) (10)
- Impact of PET/CT for Restaging Patients With Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiation. (2019) (10)
- A phase 1b/2, open label, dose-escalation study of margetuximab (M) in combination with pembrolizumab (P) in patients with relapsed/refractory advanced HER2+ gastroesophageal (GEJ) junction or gastric (G) cancer. (2017) (10)
- Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors (2021) (9)
- Survivorship: sexual dysfunction (male), version 1.2013. (2014) (9)
- A work in progress: developing the new NCCN guidelines for survivorship. (2014) (9)
- Optimal post-treatment surveillance in cancer survivors: is more really better? (2015) (9)
- 1380P Phase (Ph) II study of zanidatamab + chemotherapy (chemo) in first-line (1L) HER2 expressing gastroesophageal adenocarcinoma (GEA) (2021) (9)
- Survivorship: tools for transitioning patients with cancer. (2014) (8)
- A randomized trial of exercise and diet on health‐related quality of life in survivors of breast cancer with overweight or obesity (2021) (8)
- Patterns of use and tolerance of anti-epidermal growth factor receptor antibodies in older adults with metastatic colorectal cancer. (2014) (8)
- Second-line therapy of KRAS-mutated (KRASm) metastatic colorectal cancer (CRC) with the MEK inihibitor selumetinib ([SEL], AZ6244, ARRY-142886) in combination with irinotecan (IRI): An AGICC study. (2013) (8)
- A randomized phase II study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in advanced/metastatic colorectal cancer (mCRC) with HER2 amplification: S1613. (2018) (8)
- Gemcitabine and cisplatin plus ramucirumab or merestinib or placebo in first-line treatment for advanced or metastatic biliary tract cancer: A double-blind, randomized phase II trial. (2017) (8)
- Randomized Parallel Study of Doxorubicin Plus Paclitaxel and Doxorubicin Plus Cyclophosphamide as Neoadjuvant Treatment of Patients With Breast Cancer (2005) (7)
- Randomized open-label phase 2 study of MM-111 and paclitaxel (PTX) with trastuzumab (TRAS) in patients with HER2-expressing carcinomas of the distal esophagus, gastroesophageal (GE) junction, and stomach who have failed front-line metastatic or locally advanced therapy. (2014) (7)
- A phase I study of MM-121 in combination with multiple anticancer therapies in patients with advanced solid tumors. (2013) (7)
- A phase I study of MEDI1873, a novel GITR agonist, in advanced solid tumors. (2018) (7)
- Evolving Landscape of Systemic Therapy for Hepatocellular Carcinoma: Breakthroughs, Toxicities, and Future Frontiers. (2019) (7)
- First-in-Human Phase 1b Trial of Quinacrine Plus Capecitabine in Patients With Refractory Metastatic Colorectal Cancer. (2020) (6)
- Abstract 2947: Pharmacodynamic (PD) and pharmacokinetic (PK) results of the second-generation hypomethylating agent, SGI-110, in patients with hepatocellular carcinoma (HCC) after progression on sorafenib (2015) (6)
- Feasibility of Fitness Tracker Usage to Assess Activity Level and Toxicities in Patients With Colorectal Cancer. (2021) (6)
- Adherence to NCCN survivorship guidelines in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). (2014) (6)
- Phase I study of PF-03446962 (anti-ALK-1 mAb) in hepatocellular carcinoma (HCC). (2013) (6)
- Oxaliplatin-induced Immune Thrombocytopenia: A Case Report and Literature Review. (2020) (5)
- The MEK inhibitor selumetinib ([SEL], AZD6244, ARRY-142886) plus irinotecan (IRI) as second-line therapy for KRAS-mutated (KRASm) metastatic colorectal cancer (CRC). (2013) (5)
- Chemotherapy use and survival in older adults with metastatic pancreatic cancer in the combination therapy era. (2020) (5)
- Bgb-A425, an investigational anti-TIM-3 monoclonal antibody, in combination with tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: A phase I/II trial in progress. (2020) (5)
- Concurrent chemoradiation for resected gall bladder cancers and cholangiocarcinomas. (2018) (5)
- Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. (2020) (4)
- A randomized trial of exercise and diet on body composition in survivors of breast cancer with overweight or obesity (2021) (4)
- Quality-of-life (QoL) results from RAINFALL: A randomized, double-blind, placebo (PL)-controlled phase III study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy for metastatic gastric or gastroesophageal junction (G-GEJ) cancer. (2018) (4)
- Abstract LB-410: Phase I dose escalation study of MM-121, a fully human monoclonal antibody to ErbB3, in patients with advanced solid tumors (2011) (4)
- Targets for therapy in biliary tract cancers: the new horizon of personalized medicine. (2020) (4)
- Abstract P6-15-15: MM-111 - A Novel Bispecific Antibody Targeting HER-2/HER-3 Z Heterodimer: Safety and Tolerability in a First-In Human Phase I/II Study in Patients with Refractory HER2-Positive (HER-2+) Cancers (2010) (4)
- Physical activity intervention for patients with advanced pancreatic cancer. (2017) (4)
- P-26 RATIONALE 305: Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with gastric or gastroesophageal junction adenocarcinoma (2020) (4)
- Freedom from recurrence after induction cisplatin/5-FU/RT versus carboplatin/paclitaxel/RT in patients with esophageal cancer. (2014) (4)
- Evaluating the prognostic significance of lymphovascular invasion in stage II and III colon cancer. (2019) (4)
- Phase II study evaluating the effect of concomitant ramucirumab (RAM) on the pharmacokinetics (PK) of irinotecan (IRI) and its metabolite SN-38 when coadministered with folinic acid (FA) and 5-fluorouracil (5-FU) (FOLFIRI) in patients (pts) with advanced malignant solid tumors. (2015) (4)
- Understanding benefit finding among patients with colorectal cancer: a longitudinal study (2020) (4)
- Lack of pharmacokinetic drug–drug interaction between ramucirumab and irinotecan in patients with advanced solid tumors (2016) (3)
- Incorporating Weight Management into Clinical Care for Cancer Survivors: Challenges, Opportunities, and Future Directions (2017) (3)
- OA01.06 Safety, Efficacy, and Pharmacokinetics of AMG 510, a Novel KRASG12C Inhibitor, in Patients with Non-Small Cell Lung Cancer (2019) (3)
- Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials (2020) (2)
- Phase II study evaluating the effect of concomitant ramucirumab (IMC-1121B; RAM) on the pharmacokinetics (PK) of paclitaxel (PTX) and the PK of RAM as monotherapy in patients (pts) with advanced malignant solid tumors. (2014) (2)
- Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. (2022) (2)
- 242PBIOMARKER ANALYSIS OF A PHASE 1 STUDY OF MM-111, A BISPECIFIC HER2/HER3 ANTIBODY FUSION PROTEIN, IN COMBINATION WITH MULTIPLE TREATMENT REGIMENS IN PATIENTS WITH ADVANCED HER2 POSITIVE SOLID TUMORS. (2014) (2)
- A Case of Radiation Recall Myositis and Neuropathy in Locally Advanced Rectal Cancer (2021) (2)
- Refining Immunotherapy for the Treatment of Gastric Cancer With High Microsatellite Instability. (2021) (2)
- A phase I and pharmacologic study of MM-111, a bispecific HER2/HER3 antibody fusion protein, in combination with multiple treatment regimens in patients with advanced HER2-positive solid tumors. (2012) (2)
- Predictive value of PET/CT for pathological complete response and survival in patients with locally advanced rectal cancer. (2017) (2)
- Effect of exogenous interferon-gamma (IFN-gamma) on peripheral blood immune markers as part of a phase I clinical trial of combined IFN-gamma with nivolumab (Nivo) in patients (pts) with select solid tumors. (2017) (2)
- Concurrent Trastuzumab and Breast Radiotherapy in the Adjuvant Setting: Analysis of Acute Toxicity (2009) (2)
- Phase 1 study of PF-03446962 (anti-ALK-1 mAb) in hepatocellular carcinoma (HCC): Correlation of tumor and serum biomarker data with disease control. (2014) (2)
- Dose to Heart, Spine, Aorta, and Body Predict for Severe Lymphopenia and Poor Survival in Patients Undergoing Chemoradiation for Esophageal Cancer (2019) (2)
- Gastric and Esophageal Cancers: Guidelines Updates (2021) (2)
- Metastatic colorectal cancer (mCRC) patterns of care: Implications for clinical trial design (2007) (2)
- Intensive Dose-dense Compared With High-dose Adjuvant Chemotherapy for High-risk Operable Breast Cancer: Southwest Oncology Group/Intergroup Study 9623 (2008) (1)
- Erratum to: Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer (2014) (1)
- Demoralization and depression in pancreatic cancer patients. (2020) (1)
- Leveraging patient-reported outcomes (PROs) in patients with pancreatic cancer: The Pancreatic Cancer Action Network (PanCAN) online patient registry experience. (2020) (1)
- Neoadjuvant chemoradiation for locally advanced rectal cancer with fluoropyrimidine alone or intensified with oxaliplatin: A systematic review and meta-analysis. (2017) (1)
- Therapy Options for Patients With Hepatocellular Carcinoma. (2019) (1)
- A phase I/II study of the combination of temozolomide (TM) and pazopanib (PZ) in advanced pancreatic neuroendocrine tumors (PNETs) (NCT01465659). (2018) (1)
- Predictors of distress among individuals with gastric cancer. (2019) (1)
- Changing patterns of metastatic pancreatic cancer (mPC) care in the combination therapy era: A geriatric perspective. (2016) (1)
- Optimizing surveillance and balancing evidence with patient expectations. (2014) (1)
- Overcoming mTOR resistance: Results of a phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat. (2014) (1)
- Leveraging patient‐reported outcomes (PROs) in patients with pancreatic cancer: The Pancreatic Cancer Action Network (PanCAN) online patient registry experience (2021) (1)
- Predicted Heart Mass (PHM) Ratio for Size Matching in Heart Transplant Post LVAD (2022) (1)
- Robust Response to Futibatinib in a Patient With Metastatic FGFR-Addicted Cholangiocarcinoma Previously Treated Using Pemigatinib. (2022) (1)
- Case series of multiple primary cancers in single individuals: diagnostic and therapeutic dilemmas (2017) (1)
- P2.15-C Phase 1 Trial Evaluating Safety, Efficacy, and PK of AMG 510, a Novel KRASG12C Inhibitor, in Non-Small Cell Lung Cancer (2019) (1)
- Randomized open-label phase 2 study of MM-111 and paclitaxel (PTX) with trastuzumab (TRAS) in patients with HER2-expressing carcinomas of the distal esophagus, gastroesophageal (GE) junction, and stomach who have failed front-line metastatic or locally ad (2014) (1)
- Comparative molecular analyses of BRAF-V600E mutant tumors: Colorectal cancers (CRC) vs. melanomas. (2016) (1)
- Principles of Palliative/Best Supportive Care (2014) (1)
- Deviations From Standard Chemoradiation Among Early-Stage Anal Cancer Patients. (2017) (1)
- Use of anti-EGFR agents among elderly patients with metastatic colorectal cancer (mCRC). (2012) (1)
- Impact of Clinical Markers of Nutritional Status and Feeding Jejunostomy Use on Outcomes in Esophageal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy (2020) (1)
- Sporadic breast, ovarian, or uterine cancers as risk factors for colorectal cancer (2009) (1)
- Enhancing cancer survivorship through improved provider communication, care coordination, and professional education. (2016) (1)
- Cancer-related distress and cost of care concerns among gastric cancer patients. (2017) (1)
- Phase 1 dose escalation study of MEDI-565, a bispecific T-cell engager that targets human carcinoembryonic antigen (CEA), in patients with advanced gastrointestinal (GI) adenocarcinomas. (2016) (1)
- O-005Comparative molecular analyses of esophageal adenocarcinoma, esophageal squamous cell carcinoma, and gastric adenocarcinoma, and impact of molecular profile on outcome (2016) (1)
- Advancing More Equitable Care Through the Development of a Health Equity Report Card. (2023) (0)
- A Change of Heart. (2016) (0)
- A phase III trial-in-progress comparing tislelizumab plus chemotherapy with placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. (2019) (0)
- 3–59 Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclosphosphamide As Adjuvant Therapy for Operable Breast Cancer (2007) (0)
- Outcomes from Stereotactic Body Radiation Therapy (SBRT) for Oligometastatic Colorectal Cancer (CRC) (2019) (0)
- Factors associated with acute toxicity during chemoradiation therapy for rectal cancer. (2016) (0)
- The effects of exercise and diet on sex steroids in breast cancer survivors. (2022) (0)
- Senior Adult OncologyPractice Guidelines in Oncology (2012) (0)
- Regional Recurrence after Breast Conservation Therapy: Treatment and Patient Characteristics Affecting Outcome (2010) (0)
- Treatment decision priorities and decisional support experiences of gastric cancer survivors. (2018) (0)
- Response to Neoadjuvant Chemoradiation Increases with Age in Rectal Cancer Patients (2019) (0)
- Concurrent Chemoradiation Therapy for Resected Gall Bladder Cancers and Cholangiocarcinomas (2017) (0)
- Chemotherapy After Surgery for Stage II Colon Cancer: Clarifying the Controversy (2008) (0)
- Commentary (Denlinger/Meropol): The Horizon of Antiangiogenic Therapy for Colorectal Cancer (2005) (0)
- A dose-escalation study of imipridone ONC201 administered every one (QW) or three weeks (Q3W) in advanced solid tumors and multiple myeloma. (2017) (0)
- Feasibility of using a computerized food frequency questionnaire (FFQ) to assess dietary patterns in patients with advanced gastrointestinal (GI) malignancies. (2021) (0)
- Clinical Trials in the Age of Pandemics. (2020) (0)
- Many cancer survivors experience menopaus-NCCN Survivorship , Version 2 . 2017 Clinical Practice Guidelines in Oncology (2017) (0)
- P-103 Associations between quality-of-life, symptom burden, and demographic characteristics in long-term esophageal and gastroesophageal junction cancer survivors (2021) (0)
- HSR20-076: Provider Versus Patient Reported Outcomes (PROs) in Colorectal Cancer (CRC) Patients (pts) Undergoing Systemic Therapy (Ctx): A Real World Experience (2020) (0)
- S020) Are Early Stage Anal Cancer Patients Overtreated With Chemoradiotherapy (2017) (0)
- Feasibility of using a fitness tracker to assess activity level and toxicity in colorectal cancer patients. (2019) (0)
- The effects of exercise and diet on oxidative stress and telomere length in breast cancer survivors (2023) (0)
- Practice patterns of molecular profiling in colorectal cancer. (2017) (0)
- A phase I multicenter study of the combination of temozolomide and pazopanib in advanced pancreatic neuroendocrine tumors (PNET). (2015) (0)
- 2010 The Influenceof ExtensiveIntraductalComponenton Outcomein Patientswith EarlyStageBreast Cancer Treated with Breast Conservation Therapy (2011) (0)
- Zanidatamab + chemotherapy as first-line treatment for HER2-expressing metastatic gastroesophageal adenocarcinoma (mGEA). (2023) (0)
- Feasibility of using fitness tracker to assess activity level and toxicities in colorectal cancer (CRC) patients (Pts). (2020) (0)
- Characteristics and behavior of invasive breast cancer developed despite prior oophorectomy. (2010) (0)
- Prospective Study Evaluating Liver Radioembolization Dose with Positron Emission Tomography and Disease Response (2019) (0)
- The Olszewski/Grossbard/Kozuch article reviewed (2005) (0)
- Nutritional status and outcomes of older versus younger patients (pts) with metastatic pancreatic cancer (mPC). (2016) (0)
- Lung Cancer Survivor Experiences With Post-Treatment Care: An Integrative Review. (2022) (0)
- Stage II and III rectal adenocarcinoma outcomes related to lymphovascular invasion. (2019) (0)
- Histology Predicts Response to Chemoradiation (cRT) Regimen in Patients Undergoing Esophagectomy for Locally Advanced Esophageal Cancer (2014) (0)
- Claims-based cardiac monitoring (CM) in patients (Pts) receiving trastuzumab (TZ). (2022) (0)
- Nutrition and exercise patterns in survivors of esophageal and gastroesophageal junction (EGEJ) cancers. (2019) (0)
- Tumor profiling of liver metastases (LM) from CRC, NSCLC, pancreatic (PC), breast (BC) and gastroesophageal (GE) tumors to reveal differences versus primary tumors including in cMET, MYC, CDK4, Her2, b-catenin and PD1. (2016) (0)
- QIM19-127: Novel Admission Checklist for Malignant Bowel Obstruction (2019) (0)
- Safety and efficacy of combination of temozolomide and pazopanib in patients with advanced pancreatic neuroendocrine tumors (PNET). (2016) (0)
- Fast Facts: Cholangiocarcinoma for Patients and their Supporters (2021) (0)
- Associations of insulin-like growth factor binding proteins and adiponectin with disease progression and mortality in metastatic colorectal cancer: Results from CALGB/SWOG 80405 (Alliance). (2019) (0)
- 1155TiP Pan-tumour study CheckMate 8TT for long-term follow-up of cancer survivors who have participated in trials investigating nivolumab (2020) (0)
- A randomized phase 2 study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in advanced/metastatic colorectal cancer (mCRC) with HER2 amplification: SWOG S1613. (2023) (0)
- Predicting benefit from adjuvant therapy in colon cancer (2007) (0)
- Patterns of use and tolerance of epidermal growth factors receptor (EGFR) inhibitors among older adults with metastatic colorectal cancer (mCRC) (2012) (0)
- Elevated Hematocrit in Man Receiving Hemodialysis (2007) (0)
- Measuring liver radioembolization dose with positron emission tomography. (2019) (0)
- Quality of life (QOL) in patients with pancreatic and periampullary adenocarcinoma (PPAC). (2015) (0)
- The Influence of Extensive Intraductal Component on Outcome in Patients with Early Stage Breast Cancer Treated with Breast Conservation Therapy (2010) (0)
- A phase ib trial to evaluate the safety and efficacy of quinacrine plus capecitabine in patients with refractory metastatic colorectal cancer. (2019) (0)
This paper list is powered by the following services:
Other Resources About Crystal Denlinger
What Schools Are Affiliated With Crystal Denlinger?
Crystal Denlinger is affiliated with the following schools:
